Long-term survival and toxicity in patients with neuroendocrine tumors treated with Lu-octreotate peptide radionuclide therapy.

Background: Peptide receptor radionuclide therapy (PRRT) has shown favorable results in neuroendocrine tumors (NETs). Long-term safety and efficacy data for Lu-octreotate PRRT, particularly in combination with chemotherapy, is lacking.

Methods: The authors conducted a retrospective review of the long-term toxicity and survival outcomes of 104 patients with advanced NETs treated on 4 phase 2 clinical trials with Lutetium-177-octreotate ( Lu-octreotate) PRRT, mostly in combination with chemotherapy.

Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.

First-line (131)I-anti-CD20 radioimmunotherapy of indolent non-Hodgkin lymphoma (NHL) achieves durable remission with low toxicity. The phase II INITIAL study comprised 68 patients with follicular NHL followed up to 7 years (median 4 years) after outpatient (131)I-rituximab radioimmunotherapy (RIT) in conjunction with rituximab, followed by maintenance therapy for 1 year. Baseline and 3-month (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) imaging, analyzed according to Deauville criteria, was used to evaluate response and predict prognosis.

Changing trends in venous thromboembolism-related imaging in Western Australian teaching hospitals, 2002-2010.

Objective: To determine trends in referral for venous thromboembolism (VTE) imaging in Western Australian teaching hospitals.

Design And Setting: Retrospective audit of the WA picture archiving and communication system, PathWest Laboratory Medicine records, the hospital morbidity database at the four adult teaching hospitals in Perth, WA, and the WA death registry.

Patients: All patients referred for VTE-related imaging, and all hospital separations for pulmonary embolism (PE) during 2002-2010.